Psoriasis Clinical Trials in San Antonio

Showing 61-80 of 92 trials

Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (307)

NCT03731052

This Phase 3 study (Study 307) has been designed to determine and compare the efficacy and safety of 188-0551 Spray and Vehicle Spray applied twice daily for up to four weeks in subjects with plaque psoriasis. Subjects will be instructed to apply the test article (188-0551 Spray or Vehicle Spray) to all psoriasis plaques within the designated Treatment Area twice daily for four weeks (Study Day 29), unless the investigator verifies the subject's psoriasis has cleared at Day 15, then test article application will be for 2 weeks (Study Day 15).

Plaque Psoriasis

Therapeutics, Inc.217 participantsStarted Oct 2018

Los Angeles, California, United States • Ocala, Florida, United States • Macon, Georgia, United States +11 more locations

COMPLETEDPHASE3< 1 mile

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

NCT02515097

This study is to evaluate the safety and efficacy of a topical lotion when applied once daily to adult participants with moderate to severe plaque psoriasis (defined as an Investigator's Global Assessment \[IGA\] score of 3 or 4).

Plaque Psoriasis

Bausch Health Americas, Inc.213 participantsStarted Nov 2015

Santa Ana, California, United States • Boynton Beach, Florida, United States • Clearwater, Florida, United States +12 more locations

Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (307)

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

Psoriasis Trials in Other Cities

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis

A Trial of a Botanical Drug (EISO) for Treatment of Mild-to-Moderate Plaque Psoriasis

Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis

Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis

Multiple Ascending Dose Study of PRX003 in Subjects With Psoriasis

A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab

A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.

A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp

Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis

Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis

Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies

Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients

Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis

DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis

A Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis

Other Conditions in San Antonio